Revolo data 'reinforce potential of '1104 as groundbreaking treatment for multiple allergic diseases'

UK-based Revolo Biotherapeutics, which is developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, has announced top-line data from its allergen challenge mapping study.

This research is evaluating the immunologic mechanisms, safety, and tolerability of the company’s immune-resetting drug, ‘1104, in atopic adults with moderate to severe allergy. The goal of the trial was to further characterize the mechanism of action of ‘1104 using an atopic population undergoing allergen challenges.

"The potential to drive long-term disease remission"The trial demonstrated that ‘1104 administration led to a rapid reduction in the allergic inflammation caused by the intradermal grass pollen challenge after the first dose of ‘1104.